BSG and hepatocellular carcinoma: For example, EMMPRIN is considered a promising therapeutic target for the treatment of hepatocellular carcinoma, and monoclonal antibodies targeting EMMPRIN have made exciting clinical progress in the treatment of hepatocellular carcinoma 125.